HMGB1 and Miyoshi myopathy: Furthermore, immunohistochemical staining and ELISA demonstrated that both plasma and tumor tissue HMGB1 levels were significantly reduced in the TAK-242 treatment group (Figure 6F,G), underscoring the therapeutic potential of targeting the HMGB1-TLR4 axis in MM.